Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options

Overview of attention for article published in Frontiers in immunology, August 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

So far, Altmetric has seen 9 X posts from 9 X users, with an upper bound of 35,745 followers.

RT @FrontImmunol: Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options: Derya Kabacaog…

RT @FrontImmunol: Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options: Derya Kabacaog…

RT @FrontImmunol: Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options: Derya Kabacaog…

RT @FrontImmunol: Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options: Derya Kabacaog…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.